GALT — Galectin Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $150.40m
- $209.31m
Annual cashflow statement for Galectin Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.3 | -23.5 | -30.5 | -38.8 | -41.1 |
| Non-Cash Items | 1.8 | 1.92 | 2.47 | 2.75 | 3.42 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.641 | 0.942 | 3.75 | 4.97 | 4.68 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -10.8 | -20.6 | -24.3 | -31.1 | -33 |
| Other Investing Cash Flow Items | — | — | 0 | 0 | 0 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | — | 0 | 0 | 0 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 50.1 | 0.263 | 36.8 | 10 | 40 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 39.2 | -20.3 | 12.5 | -21.1 | 7.07 |